Honliv Healthcare Reports 16.5% Drop in Revenue and 36.1% Decrease in Gross Profit for H1 2025
Honliv Healthcare Management Group Co. Ltd. has announced its interim results for the six months ended 30 June 2025. The Group reported a revenue of RMB346.8 million, a decrease of 16.5% compared to RMB415.2 million in the same period of 2024. Gross profit also saw a decline, falling by 36.1% to RMB45.8 million from RMB71.6 million in the previous year. The Group recorded a loss attributable to owners of the company amounting to RMB673,000, contrasting with a profit of RMB20.0 million in the first half of 2024. This represents a significant change in financial performance. Pharmaceutical sales revenue for the reporting period was RMB138.7 million, reflecting a year-on-year decrease of 15.8% from RMB164.7 million. No specific outlook or guidance was included in the announcement. In terms of research and development, the Group has been active, with hospitals under its management applying for 30 new technologies and projects, of which 13 new technologies have passed the Ethics Committee review. Additionally, medical staff published 30 papers, including one SCI article, indicating ongoing commitment to medical research and development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Honliv Healthcare Management Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.